

Freedom of Information Request: Our Reference CTMUHB_294_20

Clarification requested on 21 September – we asked - Due to the way in which we collect this data, which is according to the Financial Year April to March we are only able to produce data as follows: the latest 12 months April 19 to March 20 or the latest 5 months of this Financial Year April 20 to August 20.

Please can you confirm if you require

A) The latest 12 months April 19 to March 20

Or

B) the latest 5 months of this Financial Year April 20 to August 20?

Clarification provided on 16 October – you confirmed – Please help us with the latest 5 months of this Financial Year April 20 to August 20

You asked:

I have a Freedom of Information request regarding biologic and biosimilar product prescribing in **rheumatology**.

Q1. How many patients have been treated with biologics or biosimilar products in the last 12 months (**as per the clarification provided above – the data provided is for the latest 5 months of this Financial Year April 20 to August 20**) for the following conditions:

- Rheumatoid Arthritis 420
- Psoriatic Arthritis 154
- Ankylosing Spondylitis 148
- Non-Radiographic Axial Spondyloarthritis 0

Q2. Could you please provide the numbers of patients treated by the **rheumatology** department (for any condition) in the last 12 months (**as per the clarification provided above –the data provided is for the latest 5 months of this Financial Year April 20 to August 20**) with the following drugs.

- | | |
|--------------------------|-----|
| • Abatacept [Orencia] | 23 |
| • Adalimumab [Amgevita] | 18 |
| • Adalimumab [Humira] | 167 |
| • Adalimumab [Hyrimoz] | 0 |
| • Adalimumab [Imraldi] | 38 |
| • Apremilast [Otezla] | 5 |
| • Baricitinib [Olmiant] | 18 |
| • Certolizumab [Cimzia] | 42 |
| • Etanercept [Benepali] | 145 |
| • Etanercept [Enbrel] | 28 |
| • Etanercept [Erelzi] | 0 |
| • Golimumab [Simponi] | 45 |
| • Infliximab [Flixabi] | 0 |
| • Infliximab [Inflectra] | 17 |
| • Infliximab [Remicade] | 6 |

• Infliximab [Remsima]	8
• Ixekizumab [Taltz]	0
• Rituximab [MabThera]	8
• Rituximab [Rixathon]	0
• Rituximab [Truxima]	58
• Sarilumab [Kevzara]	0
• Secukinumab [Cosentyx]	43
• Tocilizumab [Ro Actemra]	46
• Tofacitinib [Xeljanz]	11
• Upadacitinib [Rinvoq]	0
• Ustekinumab [Stelara]	7